#Sitryx
The December @immunometforum.bsky.social will
take place this Friday with three great early career researcher presenting:
🧵1/4

#immmunosky #immunoology #immunometabolism
December 10, 2024 at 3:54 PM
If you are interested in doing a PhD in metabolomics/lipidomics this might be for you - www.findaphd.com/phds/project.... Its a chance to use state of the art mass spectrometry imaging to study (and maybe treat) inflammation in adipose tissue at the Rowett Institute with Biotech company Sitryx.
EASTBIO CASE: Inflammatory Fat: Understanding how the immune system drives adipose tissue dysfunction using lipidomics at University of Aberdeen on FindAPhD.com
PhD Project - EASTBIO CASE: Inflammatory Fat: Understanding how the immune system drives adipose tissue dysfunction using lipidomics at University of Aberdeen , listed on FindAPhD.com
www.findaphd.com
December 30, 2024 at 5:42 PM
Germany's #BoehringerIngelheim could sink up to $500 million into a #partnership with UK start-up #Sitryx focused on a family of #smallmolecule drugs for #autoimmune and #inflammatory diseases.

buff.ly/QiBzfGU
February 26, 2026 at 7:00 PM
Feed: "Endpoints News"
By: ENDPOINTS on Monday, August 11, 2025
Sitryx gets back rights to drug from Lilly deal; Humacyte is cutting costs
Sitryx regains rights from Lilly for SYX-1042, Humacyte cuts 30 jobs, Equillium gets $50M financing for EQ504, and Ocugen raises $20M from Janus Henderson Investors.
endpoints.news
August 11, 2025 at 3:18 PM
We are delighted that we have been shortlisted for a Business Weekly award in the Collaboration of the Year Category based on our work with Sitryx. We supported Sitryx’s MTHFD2 programme which resulted in SIT047, a novel, oral inhibitor, progressing to clinical development for psoriatic arthritis.
July 31, 2025 at 9:31 AM
LucidQuest Views >>> Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal Comment below! #LucidQuest #PharmaCI
Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal
Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal Professional audiences only. Not investment research or advice. UK readers: […] The post Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal appeared first on LucidQuest Ventures.
dlvr.it
February 27, 2026 at 8:35 AM
Thoughts on this? >> Sitryx gets back rights to drug from Lilly deal; Humacyte is
cutting costs >> Comment below! #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #healthcare #pharma
Sitryx gets back rights to drug from Lilly deal; Humacyte is cutting costs
Plus, news about Equillium and Ocugen: Sitryx Therapeutics regains rights to itaconate mimetic: The company had inked a deal with Eli Lilly in 2020 to work on immunometabolic medicines. It
dlvr.it
August 11, 2025 at 4:01 PM
Boehringer bets on immunometabolism with $500M-plus Sitryx pact firstwordpharma.com/story/7116016
February 26, 2026 at 10:42 PM